These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23306325)

  • 41. The role of preclinical atherosclerosis in the explanation of educational differences in incidence of coronary events.
    Rosvall M; Engström G; Hedblad B; Janzon L; Göran B
    Atherosclerosis; 2006 Aug; 187(2):251-6. PubMed ID: 16242699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?
    Kim G; Youn HJ; Choi YS; Jung HO; Chung WS; Kim CM
    Clin Interv Aging; 2015; 10():1111-9. PubMed ID: 26185430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.
    Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Steg PG; Cannon CP; Brennan DM; Bhatt DL;
    Crit Pathw Cardiol; 2009 Jun; 8(2):91-7. PubMed ID: 19417637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.
    Alberts MJ; Bhatt DL; Mas JL; Ohman EM; Hirsch AT; Röther J; Salette G; Goto S; Smith SC; Liau CS; Wilson PW; Steg PG;
    Eur Heart J; 2009 Oct; 30(19):2318-26. PubMed ID: 19720633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of neutrophils in patients with asymptomatic carotid artery disease.
    Mayer FJ; Gruenberger D; Schillinger M; Mannhalter C; Minar E; Koppensteiner R; Arbesú I; Niessner A; Hoke M
    Atherosclerosis; 2013 Dec; 231(2):274-80. PubMed ID: 24267239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease.
    Keo HH; Baumgartner I; Hirsch AT; Duval S; Steg PG; Pasquet B; Bhatt DL; Roether J;
    Vasc Med; 2011 Oct; 16(5):323-30. PubMed ID: 21908682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol.
    Rizzo M; Corrado E; Coppola G; Muratori I; Novo G; Novo S
    Atherosclerosis; 2008 Oct; 200(2):389-95. PubMed ID: 18258237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: the role of C-reactive protein.
    Rizzo M; Corrado E; Coppola G; Muratori I; Novo S
    J Investig Med; 2008 Jan; 56(1):32-40. PubMed ID: 18317426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.
    Suárez C; Zeymer U; Limbourg T; Baumgartner I; Cacoub P; Poldermans D; Röther J; Bhatt DL; Steg PG;
    Vasc Med; 2010 Aug; 15(4):259-65. PubMed ID: 20724374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry.
    Gaxiola E; Eng-Ceceña L; Ortiz-Galván F; Llamas-López L; Rangel-Guerra R; Alcocer-Gamba MA; Bhatt DL; Gabriel Steg P;
    Clin Cardiol; 2010 Jul; 33(7):445-51. PubMed ID: 20641123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
    Cacoub PP; Abola MT; Baumgartner I; Bhatt DL; Creager MA; Liau CS; Goto S; Röther J; Steg PG; Hirsch AT;
    Atherosclerosis; 2009 Jun; 204(2):e86-92. PubMed ID: 19054514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
    Smolderen KG; Bell A; Lei Y; Cohen EA; Steg PG; Bhatt DL; Mahoney EM;
    Can J Cardiol; 2010 Oct; 26(8):297-305. PubMed ID: 20931098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry.
    Venketasubramanian N; Röther J; Bhatt DL; Pasquet B; Mas JL; Alberts MJ; Hill MD; Aichner F; Steg PG;
    Cerebrovasc Dis; 2011; 32(3):254-60. PubMed ID: 21876353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
    Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
    Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of glomerular filtration rate on clinical outcomes after carotid artery revascularization in 11,832 patients from the CARE registry.
    Gruberg L; Jeremias A; Rundback JH; Anderson HV; Spertus JA; Kennedy KF; Rosenfield KA
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):246-54. PubMed ID: 23813603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry.
    Ruff CT; Bhatt DL; Steg PG; Gersh BJ; Alberts MJ; Hoffman EB; Ohman EM; Eagle KA; Lip GY; Goto S;
    Int J Cardiol; 2014 Jan; 170(3):413-8. PubMed ID: 24321327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sex is associated with the presence of atherosclerotic plaque hemorrhage and modifies the relation between plaque hemorrhage and cardiovascular outcome.
    Vrijenhoek JE; Den Ruijter HM; De Borst GJ; de Kleijn DP; De Vries JP; Bots ML; Van de Weg SM; Vink A; Moll FL; Pasterkamp G
    Stroke; 2013 Dec; 44(12):3318-23. PubMed ID: 24130138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis.
    Amighi J; Hoke M; Mlekusch W; Schlager O; Exner M; Haumer M; Pernicka E; Koppensteiner R; Minar E; Rumpold H; Schillinger M; Wagner O
    Stroke; 2011 Jul; 42(7):1826-33. PubMed ID: 21546482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The SYNTAX score does not predict presence of carotid disease in a multivessel coronary disease population.
    Costanzo L; Campisano MB; Capodanno D; Sole A; Grasso C; Ragusa M; Ronsivalle G; Tamburino C; Tamburino C; Di Pino L
    Catheter Cardiovasc Interv; 2014 Jun; 83(7):1169-75. PubMed ID: 24323404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammation, atherosclerotic burden and cardiovascular prognosis.
    Espinola-Klein C; Rupprecht HJ; Bickel C; Lackner K; Schnabel R; Munzel T; Blankenberg S;
    Atherosclerosis; 2007 Dec; 195(2):e126-34. PubMed ID: 17336309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.